Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

GlaxoSmithKline PLC Director's Dealing 2017

Oct 16, 2017

5262_dirs_2017-10-16_4cbee499-8bf3-44f7-a445-ee12f3d4f3ad.html

Director's Dealing

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 7388T

GlaxoSmithKline PLC

16 October 2017

GlaxoSmithKline plc (the 'Company')

Transaction notification

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms E Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s) Volume(s)
£15.275 75.595 (personal contribution)
£15.275 187.204 (personal contribution)
£15.275 203.821 (personal contribution)
£15.275 75.595 (personal contribution)
£15.275 187.191 (personal contribution)
£15.275 203.809 (personal contribution)
£15.275 75.595 (matching shares)
£15.275 187.204 (matching shares)
£15.275 203.821 (matching shares)
£15.275 75.595 (matching shares)
£15.275 187.191 (matching shares)
£15.275 203.809 (matching shares)

d)

Aggregated information

Aggregated volume Price

1,866.43

£15.275

e)

Date of the transaction

2017-10-12

f)

Place of the transaction

n/a

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R G Connor

b)

Position/status

President, Global Manufacturing & Supply

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s) Volume(s)
£15.275 55.361 (personal contribution)
£15.275 127.190 (personal contribution)
£15.275 106.128 (personal contribution)
£15.275 55.361 (personal contribution)
£15.275 106.115 (personal contribution)
£15.275 55.361 (matching shares)
£15.275 127.19 (matching shares)
£15.275 106.128 (matching shares)
£15.275 55.361 (matching shares)
£15.275 106.115 (matching contribution)

d)

Aggregated information

Aggregated volume Price

900.310

£15.275

e)

Date of the transaction

2017-10-12

f)

Place of the transaction

n/a

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr L Debruyne

b)

Position/status

President, Global Vaccines

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s) Volume(s)
£15.275 178.377 (personal contribution)
£15.275 178.365 (personal contribution)
£15.275 178.377 (matching shares)
£15.275 178.365 (matching shares)

d)

Aggregated information

Aggregated volume Price

713.484

£15.275

e)

Date of the transaction

2017-10-12

f)

Place of the transaction

n/a

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr S Dingemans

b)

Position/status

Chief Financial Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s) Volume(s)
£15.275 105.590 (personal contribution)
£15.275 247.218 (personal contribution)
£15.275 185.166 (personal contribution)
£15.275 105.576 (personal contribution)
£15.275 247.205 (personal contribution)
£15.275 185.166 (personal contribution)
£15.275 105.590 (matching shares)
£15.275 247.218 (matching shares)
£15.275 185.166 (matching shares)
£15.275 105.576 (matching shares)
£15.275 247.205 (matching shares)
£15.275 185.166 (matching shares)

d)

Aggregated information

Aggregated volume Price

2,151.842

£15.275

e)

Date of the transaction

2017-10-12

f)

Place of the transaction

n/a

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr N Hirons

b)

Position/status

SVP, Global Ethics & Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s) Volume(s)
£15.275 38.762 (personal contribution)
£15.275 91.407 (personal contribution)
£15.275 67.081 (personal contribution)
£15.275 38.762 (personal contribution)
£15.275 91.407 (personal contribution)
£15.275 67.068 (personal contribution)
£15.275 38.762 (matching shares)
£15.275 91.407 (matching shares)
£15.275 67.081 (matching shares)
£15.275 38.762 (matching shares)
£15.275 91.407 (matching shares)
£15.275 67.068 (matching shares)

d)

Aggregated information

Aggregated volume Price

788.974

£15.275

e)

Date of the transaction

2017-10-12

f)

Place of the transaction

n/a

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr B McNamara

b)

Position/status

CEO, GSK Consumer Healthcare

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053 

b)

Nature of the transaction

Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 12 October 2017 on ADSs held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s) Volume(s)
$41.020 75.963 (personal contribution)
$41.020 75.963 (matching shares)

d)

Aggregated information

Aggregated volume Price

151.926

$41.020

e)

Date of the transaction

2017-10-12

f)

Place of the transaction

n/a

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D S Redfern

b)

Position/status

Chief Strategy Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s) Volume(s)
£15.275 62.115 (personal contribution)
£15.275 116.331 (personal contribution)
£15.275 84.422 (personal contribution)
£15.275 62.115 (personal contribution)
£15.275 116.331 (personal contribution)
£15.275 84.409 (personal contribution)
£15.275 62.115 (matching shares)
£15.275 116.331 (matching shares)
£15.275 84.422 (matching shares)
£15.275 62.115 (matching shares)
£15.275 116.331 (matching shares)
£15.275 84.409 (matching shares)

d)

Aggregated information

Aggregated volume Price

1,051.446

£15.275

e)

Date of the transaction

2017-10-12

f)

Place of the transaction

n/a

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms C Thomas

b)

Position/status

SVP, Human Resources

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s) Volume(s)
£15.275 83.607 (personal contribution)
£15.275 170.189 (personal contribution)
£15.275 127.067 (personal contribution)
£15.275 83.594 (personal contribution)
£15.275 170.189 (personal contribution)
£15.275 127.067 (personal contribution)
£15.275 83.607 (matching shares)
£15.275 170.189 (matching shares)
£15.275 127.067 (matching shares)
£15.275 83.594 (matching shares)
£15.275 170.189 (matching shares)
£15.275 127.067 (matching shares)

d)

Aggregated information

Aggregated volume Price

1,523.426

£15.275

e)

Date of the transaction

2017-10-12

f)

Place of the transaction

n/a

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr P C Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s) Volume(s)
£15.275 56.787 (personal contribution)
£15.275 104.127 (personal contribution)
£15.275 79.994 (personal contribution)
£15.275 56.787 (matching shares)
£15.275 104.127 (matching shares)
£15.275 79.994 (matching shares)

d)

Aggregated information

Aggregated volume Price

481.816

£15.275

e)

Date of the transaction

2017-10-12

f)

Place of the transaction

n/a

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D E Troy

b)

Position/status

SVP & General Counsel

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053

b)

Nature of the transaction

Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 12 October 2017 on ADSs held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s) Volume(s)
$41.020 43.227 (personal contribution)
$41.020 97.329 (personal contribution)
$41.020 80.611 (personal contribution)
$41.020 43.227 (personal contribution)
$41.020 97.329 (personal contribution)
$41.020 80.599 (personal contribution)
$41.020 43.227 (matching shares)
$41.020 97.329 (matching shares)
$41.020 80.611 (matching shares)
$41.020 43.227 (matching shares)
$41.020 97.329 (matching shares)
$41.020 80.599 (matching shares)

d)

Aggregated information

Aggregated volume Price

884.644

$41.020

e)

Date of the transaction

2017-10-12

f)

Place of the transaction

n/a

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr P J T Vallance

b)

Position/status

President, R&D

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s) Volume(s)
£15.275 123.070 (personal contribution)
£15.275 200.197 (personal contribution)
£15.275 138.016 (personal contribution)
£15.275 123.070 (personal contribution)
£15.275 200.197 (personal contribution)
£15.275 138.016 (personal contribution)
£15.275 123.070 (matching shares)
£15.275 200.197 (matching shares)
£15.275 138.016 (matching shares)
£15.275 123.070 (matching shares)
£15.275 200.197 (matching shares)
£15.275 138.016 (matching shares)

d)

Aggregated information

Aggregated volume Price

1,845.132

£15.275

e)

Date of the transaction

2017-10-12

f)

Place of the transaction

n/a

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHEQLFFDBFEFBF